Generex Biotechnology Corporation Appoints Mark J. Prioletti to the Board of Directors
April 08 2019 - 9:13AM
InvestorsHub NewsWire
Generex Biotechnology Corporation
Appoints Mark J. Prioletti to the Board of Directors
Sales & Marketing
Executive Brings Global Expertise in Global Channel
Marketing
MIRAMAR, FL -- April 8, 2019 -- InvestorsHub NewsWire -- Generex
Biotechnology Corporation (www.generex.com) (OTCQB: GNBT)
(http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce
the appointment of Mark J. Prioletti to the Board of
Directors. He is a highly experienced marketing and business
professional with over 35 years of success in the wireless
communications industry for government, enterprise, and consumer
segments in both the US and International markets. Mr. Prioletti
had a distinguished career at Motorola, leading Channel Marketing
& Sales, New Program Development, Partnership and Alliance
Development to vastly expand the Motorola sales operations, which
continually generated profitable revenue and growth for both
emerging markets and mature businesses. With exceptionally strong
skills in marketing strategy and sales operation, Mr. Prioletti
adds valuable expertise to the Board of Directors.
“Mark Prioletti brings a wealth of sales and marketing
experience and expertise to our Board of Directors,” said Joseph
Moscato, President & CEO of Generex Biotechnology. “In his long
and successful career at Motorola, he was part of the mobile
revolution that changed the communications industry, launching and
promoting paging and cellular technologies throughout the U.S.,
Europe, Asia, and Australia. As we build Generex and the NuGenerex
family of companies as an end-to-end solutions provider in
healthcare, Mark will provide valuable insight in consumer
engagement and channel marketing, and we look forward to working
with him on the Board.”
Mr. Prioletti commented on his appointment to the Generex Board,
“I am drawn to Joe’s vision to build Generex as an integrated life
science holdings company. The company has done an amazing job
establishing the business foundation for a transformational
approach to healthcare. As in the cellular space, it is essential
to embrace technology and engage customers across the spectrum of
the industry, from manufacturers to healthcare systems, to
physicians and patients, and I hope to provide experience and
guidance to Joe and his management team as we grow Generex for the
future.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding
company with end-to-end solutions for patient centric care from
rapid diagnosis through delivery of personalized therapies. Generex
is building a new kind of healthcare company that extends beyond
traditional models providing support to physicians in an MSO
network, and ongoing relationships with patients to improve the
patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology
assets, medical devices, and diagnostics, the Company is focused on
an acquisition strategy of strategic businesses that complement
existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services
organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex
Distribution Solutions (NDS), integrates our MSO network with a
pharmacy network, clinical diagnostic lab, durable medical
equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking
Statements
This release and oral statements made from time to time by
Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan,"
"believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they
do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private
Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Apr 2023 to Apr 2024